10.2337/diabetes.53.3.654 44
The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan to receive various doses of orforglipron or placebo along with healthy diet and physical activity
Additionally, the oral GLP-1 is also being evaluated as a possible treatment for obstructive sleep apnea and hypertension among individuals with obesity
For type 2 diabetes management , NICE guidance (NG28) recommends GLP-1 agonists as second- or third-line therapy when metformin and other oral agents provide inadequate glycaemic control, or as an alternative to insulin in appropriate patients
The progesterone safety concern This is where things get serious
Step 2: Provider Review